Prana Biotechnology Ltd (PRAN)

4.38
NASDAQ : Health Care
Prev Close 4.38
Day Low/High 0.00 / 0.00
52 Wk Low/High 2.70 / 7.38
Avg Volume 38.10K
Exchange NASDAQ
Shares Outstanding 8.90M
Market Cap 39.06M
EPS -0.50
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Prana Chief Scientific Advisor Receives Smithsonian American Ingenuity Award

Prana Chief Scientific Advisor Receives Smithsonian American Ingenuity Award

Prana Biotechnology Limited (ASX:PBT/NASDAQ:PRAN) is pleased to congratulate its Chief Scientist, Professor Rudy Tanzi, who has been awarded a Smithsonian American Ingenuity Award for his work researching Alzheimer's...

Anavex Presents Meaningless Results in Alzheimer's Drug Study

Anavex Presents Meaningless Results in Alzheimer's Drug Study

'The chance you would have gotten similar data giving the patients 10 cups of coffee a day instead? Almost 100%,' said Dr. Adam Kline, a researcher who reviewed the data.

Prana Receives Non-Compliance Notice Regarding NASDAQ Minimum Bid Price Requirement

Prana Receives Non-Compliance Notice Regarding NASDAQ Minimum Bid Price Requirement

Prana Biotechnology Limited (ASX:PBT/NASDAQ:PRAN) has received notification from the Listing Qualifications Department of NASDAQ advising the Company that it is currently non-compliant with NASDAQ's requirement that listed...

Prana Reports FY15 Financial Results

Prana Reports FY15 Financial Results

Prana Biotechnology Limited (ASX:PBT) (NASDAQ:PRAN) yesterday announced its financial results for the 12 months to June 30, 2015.

Prana Announces Safety Outcomes Of Alzheimer's IMAGINE Extension Trial

Prana Announces Safety Outcomes Of Alzheimer's IMAGINE Extension Trial

Prana Biotechnology (ASX:PBT) (NASDAQ:PRAN) has today announced the safety outcomes of the IMAGINE Extension study in patients with Alzheimer's disease.

European Commission Approves PBT2 Orphan Designation For Huntington's Disease

European Commission Approves PBT2 Orphan Designation For Huntington's Disease

Prana Biotechnology Limited (ASX:PBT/NASDAQ:PRAN) has today announced that the European Commission has approved orphan designation for PBT2 for the treatment of Huntington's disease, stating that Prana has shown that PBT2...

PBT2 Recommended For Orphan Designation In Europe

PBT2 Recommended For Orphan Designation In Europe

Prana Biotechnology (ASX:PBT) (NASDAQ:PRAN) is pleased to announce the European Medicines Agency's Committee for Orphan Medicinal Products (COMP) has adopted a positive opinion recommending designation of PBT2 for the...

4 Stocks Under $10 to Trade for Big Breakouts

4 Stocks Under $10 to Trade for Big Breakouts

These under-$10 stocks are within range of triggering breakout trades.

The Lancet Neurology Publishes Prana's Huntington Disease Trial

The Lancet Neurology Publishes Prana's Huntington Disease Trial

Prana Biotechnology (ASX:PBT)(NASDAQ:PRAN) has today announced the results of its Phase 2 trial in Huntington Disease, REACH2HD, has been published online in one of the world's leading medical journals, The Lancet...

Why Prana Biotechnology (PRAN) Stock Is Surging Today

Why Prana Biotechnology (PRAN) Stock Is Surging Today

Shares of Prana Biotechnology (PRAN) soared 26.17% to $2.70 in morning trading Friday after the company announced the FDA granted Orphan Drug designation to PBT2 to treat Huntington Disease.

3 Biotech Stocks Under $10 in Breakout Territory

3 Biotech Stocks Under $10 in Breakout Territory

These under-$10 biotech stocks are within range of triggering breakout trades.

Why Prana Biotechnology (PRAN) Stock Is Surging Today

Why Prana Biotechnology (PRAN) Stock Is Surging Today

Prana Biotechnology (PRAN) surged Thursday after the company announced a new sub-analysis of its failed study Phase II of PBT2 in Alzheimer's disease.

5 Stocks Under $10 Set to Soar

5 Stocks Under $10 Set to Soar

These under-$10 stocks look ready to break out and trade higher from current levels.

5 Stocks Under $10 Setting Up to Soar

5 Stocks Under $10 Setting Up to Soar

These under-$10 stocks look poised to break out and trade higher from current levels.

4 Stocks Under $10 to Trade for Breakouts

4 Stocks Under $10 to Trade for Breakouts

These under-$10 stocks are within range of triggering breakout trades.

3 Stocks Under $10 Making Big Moves

3 Stocks Under $10 Making Big Moves

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

Here's the Next Small-Cap Stock the Spec Money Will Chase

Here's the Next Small-Cap Stock the Spec Money Will Chase

Speculative money has returned to the markets with a vengeance in the small-cap arena.

Prana Biotechnology (PRAN) Stock Suddenly Surges

Prana Biotechnology (PRAN) Stock Suddenly Surges

Prana Biotechnology (PRAN) is surging today despite a lack of any significant news regarding the company, which develops drugs to treat neurodegenerative diseases.

A Beaten-Down Biotech Stock Poised to Perk Up

A Beaten-Down Biotech Stock Poised to Perk Up

The biotech sector is back in vogue today. Keep this beaten-down biotech stock on your radar.

3 Stocks Under $10 Making Big Moves

3 Stocks Under $10 Making Big Moves

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

Biotech Stock Mailbag: Celgene, IsoRay, Northwest Bio, Bubble Worries

Biotech Stock Mailbag: Celgene, IsoRay, Northwest Bio, Bubble Worries

Biotech columnist Adam Feuerstein answers readers' questions about health care companies.

Why Prana Biotechnology (PRAN) Stock Is Down Today

Why Prana Biotechnology (PRAN) Stock Is Down Today

Prana Biotechnology (PRAN) continued to decline on Tuesday after the company announced on Monday its phase II study of PBT2 in Alzheimer's disease failed. The experimental drug did not reach the study's main endpoint of a statistically significant reduction in beta amyloid plaque levels in patients' brains with prodromal or mild Alzheimer's. PBT2 also did not show an improvement in brain metabolic activity, cognition or function when compared to a placebo.

Prana Alzheimer's Study Fails

Prana Alzheimer's Study Fails

The experimental drug PBT2 failed to reduce beta amyloid plaque in the brain and couldn't improve cognition or function in Alzheimer's patients.

First Week Of November 22nd Options Trading For Prana Biotechnology (PRAN)

First Week Of November 22nd Options Trading For Prana Biotechnology (PRAN)

Investors in Prana Biotechnology Ltd saw new options begin trading this week, for the November 22nd expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 240 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

A Busy Calendar of March Biotech Events

A Busy Calendar of March Biotech Events

Drug approvals, FDA advisory panels and clinical trial results all on tap over the next 30 days.

First Week of April 19th Options Trading For Prana Biotechnology (PRAN)

First Week of April 19th Options Trading For Prana Biotechnology (PRAN)

Investors in Prana Biotechnology Ltd saw new options begin trading this week, for the April 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the PRAN options chain for the new April 19th contracts and identified one put and one call contract of particular interest.

Biotech Stock Mailbag: Raptor, Chelsea, Oncogenex, More Hate Mail!

Biotech Stock Mailbag: Raptor, Chelsea, Oncogenex, More Hate Mail!

Biotech columnist Adam Feuerstein answers readers' questions about health care companies.